Forte Medical joins ABHI UK Healthcare Pavilion

The Association of British HealthTech Industries (ABHI) recently launched the UK Healthcare Pavilion, a single platform to unite MedTech companies with the UK healthcare sectors, both NHS and private. Forte Medical is very happy to have joined such an august and respected portfolio of companies, providers and innovators.  Our entry features films about our technology featuring advocates, policy makers, healthcare professionals and the AHSN Network. Click here to view.

US Partnership Deal With Owen Mumford Announced

The partnership between Forte Medical and Owen Mumford USA was launched today at the OCTANe Medical Innovation Technology Forum (MTIF) at Newport Beach, CA 28-29 October 2019. 

Introducing Peezy Midstream to the USA has long been an ambition of Forte Medical. Our disruptive and innovative MedTech called for a partner with experience, knowledge and a savvy mindset. We found that partner in Atlanta-based Owen Mumford USA whose reach covers the USA and Canada and is managed by Travis Shaw.

Owen Mumford has been at the forefront of medical device innovation for over 65 years, creating solutions that improve the delivery of healthcare and home health treatments for people around the world. Their products span devices that make blood testing more comfortable to solutions that make it easier to administer life-saving medication.

Owen Mumford’s experience in medical devices began in the 1950s when founders Ivan Owen and John Mumford established the company. The company have direct sales offices and a network of distribution partners serving customers in over 60 countries, and employ over 800 people across the Americas, Europe and Asia.  

“Owen Mumford USA is delighted to partner Forte Medical in North America and Canada,” says Travis Shaw. “Our team looks forward to expanding our mutual synergies. Research indicates that Peezy Midstream can add significant clinical and cost value to healthcare providers, a true win-win for all parties.”
 
Thanks to the Greater Irvine Chamber of Commerce for making this possible.

Antibiotics and urinary tract infections

Antibiotics, better tests, UTI: Guardian publishes Forte response

A rise in persistent UTIs could be linked to antibiotic crackdown appeared in The Guardian on Saturday 5th October. As usual, no-one mentioned accurate basic specimen collection, which can lead to unwarranted specimen quality variation, failed analysis and less-than-targeted prescribing. Giovanna Forte had something to say. Click here to read her published letter.

urine infection medication

Comment On Incentivising Companies To Develop New Antibiotics

It is very interesting to read that pharma companies are to be incentivised to develop new antibiotics to combat antimicrobial resistance (AMR). A significant yet consistently overlooked contribution to the problem of AMR is unreliable urine collection and analysis, which leads to the staggeringly high rates of broad-spectrum antibiotic prescribing that is fuelling the AMR crisis.

NHS Improvement data confirms that 50% of the global rise in AMR has a urinary source and that Urinary Tract Infection (UTI) is being routinely treated with increasingly pointless broad spectrum antibiotics.

All NHS and Public Health England guidelines specify that midstream urine is required for accurate analysis. There is no guarantee that this occurs as there is no protocol for urine collection. We know from a 2016 FOI request to all NHS Trusts that urine specimen contamination rates reach as high as 70%, with an average of 23%. This means 15m people a year are not being accurately diagnosed and are generally prescribed a broad spectrum antibiotic that will not treat their condition.

Some years ago, in response to failed UTI treatment amongst his patients, a diligent NHS GP identified this problem and invented a low-cost, British made medical device that collects midstream urine specimens. It has taken almost 15 years for us to persuade the NHS that his device is worth using; clinical trial results confirm its efficacy and substantial cost savings due to reduced retesting and false-positive urine specimens. Our world-first device delivers win-win for diagnostics, clinicians, patients, AMR and NHS finances all for 87p. Can the pharma companies compete with this?

Before the Government “incentivises” the already well-off pharma industry to develop new medicines, it would do well to get the basics right and look to NHS generated innovation to help it succeed. As it happens, our British SME is looking for investment; perhaps the Government would instead like to incentivise our work in delivering a tangible, ready-made solution for this global problem?

Urine specimen testing

Urine Is Liquid Gold When It Comes To Testing

Today’s Hippocratic Post features an overview on the importance of urine and the evidence supporting why our technology plays such a vital role in enabling right-first-time diagnosis and treatment.

 

Infection prevention and control

IPC 2019 – We’re Exhibiting!

The future of preventative care, infection control, antimicrobial resistance and patient safety are routinely undermined by lazy attitudes towards urine collection, the most common diagnostic process.    Despite mounting evidence to support the need for a respected protocol, incumbent methods are failing modern medicine, patient health and the work of diligent clinicians.

Want to know more about our mission – visit us on stand 23 – and see first hand our world-class diagnostic specimen collection technology; Peezy Midstream reduces false-positive dipped urines by almost 70% and specimen contamination to just 2%. Current contamination is 23.5%, leading to 1 in 4 failed urine specimens – that’s over 14m annually or 56,000 every day. The unique Peezy Midstream delivers diagnostic integrity leading to targeted treatment; it helps address growing problems of infection control, unnecessary broad-spectrum antibiotic prescribing, AMR, and failed treatment of conditions that can become chronic.

Gionvanni Forte at no. 10

To No 10 for the LS Industrial Strategy Reception

Today, Forte Medical’s Chief Executive Giovanna Forte attended the Life Sciences Industrial Strategy reception at No 10 Downing Street – creating the foundation for brilliant innovation and MedTech

Forte Medical UCI conference

Attending the Greater Irvine Chamber’s 2018 Life Sciences

Giovanna Forte, CEO was delighted to be one of 10 British executives to make their way to UC Irvine (UCI) for the Greater Irvine Chamber’s 2018 Life Science Showcase event.

In collaboration with UCI Applied Innovation, the Greater Irvine Chamber hosted UK owned life science companies to position Southern California and UCI as a strong global brand for innovation and entrepreneurship. Applied Innovation worked closely with the chamber to promote industry cluster growth in the region.

Click here to read more about the event

Forte Medical Peezy Midstream on TV

Case Study – NIHR Support

A little while ago, the NIHR supported Forte Medical Ltd on a usability study for the Peezy™ Mid-Stream Urine device – an easier, cleaner and more reliable urine sample collection.   This is the interview filmed with Giovanna Forte last week.

 

The study: https://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/work-with-leading-academic-and-clinical-research-experts/nihr-medtech-services/medtech-case-studies/forte-medical.htm

 

“Maximising Our Medtech Might”

The NHS National Institute for Health Research (NIHR) will be holding their national industry event on 10th October and our CEO, Giovanna Forte will be participating in the session focusing on “Maximising Our Medtech Might”.

The theme for this year’s event is: The Future Now and provides a platform to discuss the latest developments and opportunities in the UK clinical research environment. We’ll be examining the new era of clinical trials, focussing our lens on patient centricity and asking ‘where is clinical development heading next?’

Click for further information on the NIHR CRN National Industry Event 2018